Hormones, E.g., Prolactin, Thymosin, Growth Factors, Etc. Patents (Class 530/399)
  • Patent number: 10138283
    Abstract: Modified bovine G-CSF polypeptides and uses thereof are provided.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: November 27, 2018
    Assignees: AMBRX, INC., ELANCO US INC.
    Inventors: Anna-Maria A. Hays Putnam, Nick Knudsen, Thea Norman, Alan Koder, Vadim Kraynov, Lillian Ho, Peter C. Canning
  • Patent number: 10125168
    Abstract: Provided is a method for adjusting the balance of TNF-R1 and TNF-R2 in cells present at a target organ, tissue or site. In the adjustment method provided, when increasing the relative presence of TNF-R2 compared to the presence of TNF-R1 in the cells, a synthetic peptide is supplied to the cells, with the peptide being essentially made of at a TNF-R1 signal peptide motif or a modified amino acid sequence thereof; and when decreasing the relative presence of TNF-R2 compared to the presence of TNF-R1 in the cells, a synthetic peptide is supplied to the cells, with the peptide being essentially made of a TNF-R2 signal peptide motif or a modified amino acid sequence thereof.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: November 13, 2018
    Assignee: TOAGOSEI CO. LTD.
    Inventors: Nahoko Kobayashi, Tetsuhiko Yoshida
  • Patent number: 10059756
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: August 28, 2018
    Assignee: Acceleron Pharma Inc.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
  • Patent number: 9969799
    Abstract: The present invention provides an anti-human proBDNF monoclonal antibody, and uses thereof in pains. Specifically, the present invention provides uses of antibody polypeptide of tenth to 128th amino acid in a specific recognition pro-BDNF precursor protein structural domain, a nucleic acid sequence for coding the antibody polypeptide, a carrier comprising the nucleic acid sequence, a host comprising the carrier, a pharmaceutical composition comprising the antibody, and the antibody in the preparation of drugs used for alleviating and/or suppressing chronic pains.
    Type: Grant
    Filed: January 4, 2015
    Date of Patent: May 15, 2018
    Assignee: Shanghai Yile Biotechnology Limited
    Inventors: Huamao Wang, Ruping Dai, Zonghai Li
  • Patent number: 9757418
    Abstract: In vitro and in vivo application of sub-atmospheric, negative pressure on growth factor starting material, such as whole blood, extracts growth factors from the platelet granules of the growth factor starting material in a non-destructive medium without activating the clotting process. The extracted growth factors are released into a growth factor composition containing blood plasma, extracellular fluid or interstitial fluid depending upon the type and location of the growth factor starting material. The growth factors have a weight of about 70-76 kDaltons and are applied in either a filtered or unfiltered state topically to the area of a surface wound to effect healing. The extracted growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by lyophilization.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: September 12, 2017
    Inventors: Gary H. Nelson, Ryan N Brandt, Clark Galen, John Kiwczak
  • Patent number: 9705155
    Abstract: According to one embodiment, a solid electrolyte secondary battery includes a positive electrode, a negative electrode, and a solid electrolyte layer, wherein at least one selected from the positive electrode and the negative electrode comprises active material particles, first solid electrolyte particles located the vicinity of a surface of the active material particles, and second solid electrolyte particles located a gap between the active material particles. A particle size ratio of a second solid electrolyte particle size D2 to a first solid electrolyte particle size D1 (D2/D1) satisfies the relation of 3<D2/D1<50, where D1 and D2 denote a particle size of the first and second solid electrolyte particles, respectively.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 11, 2017
    Assignee: KABUSHIKI KAISHA TOSHIBA
    Inventors: Keigo Hoshina, Hiroki Inagaki, Norio Takami
  • Patent number: 9694038
    Abstract: Acute and chronic diseases of the organs are treated in patients using a rational, multi-tier approach. A patient can be pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells or other cell therapy. The patient can be a fetus treated in utero or removed from the womb. The progress of treatment is monitored by ultrasound, MRI, CAT scan, cardiac echo, EEG, EKG, EMG or blood tests, with growth factor treatment and/or stem cell administration adjusted according to the results of the monitoring or clinical status of the patient.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: July 4, 2017
    Inventor: Wayne P. Franco
  • Patent number: 9657078
    Abstract: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidiodacetic acid group, or 4) a moiety of formula (ZyHisw)p (SEQ ID NO: 50), wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: May 23, 2017
    Assignee: PHARMAIN CORPORATION
    Inventors: Gerardo M. Castillo, Elijah Bolotin
  • Patent number: 9644014
    Abstract: Modified animal erythropoietin polypeptides and uses thereof are provided.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: May 9, 2017
    Assignees: Ambrx, Inc., Eli Lilly and Company
    Inventors: Feng Tian, Anna-Maria A. Hays Putnam, Frank Song, Stephanie Chu, Joseph Sheffer, Richard S. Barnett, Marc Siladi, Kyle Atkinson, Darin Lee, Peter C. Canning
  • Patent number: 9637441
    Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid of Formula (I), and methods for making such non-natural amino acids and polypeptides.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: May 2, 2017
    Assignee: AMBRX, INC.
    Inventors: Zhenwei Miao, Junjie Liu, Thea Norman, Russell Driver
  • Patent number: 9573986
    Abstract: The present invention provides a peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: February 21, 2017
    Assignee: KENJI KANGAWA
    Inventors: Kenji Kangawa, Masayasu Kojima, Hiroshi Hosoda, Hisayuki Matsuo, Yoshiharu Minamitake
  • Patent number: 9540428
    Abstract: Heparin binding peptides derived from a Tenascin (TNC) III1-5 domain or a fibrinogen ?15-66 domain have been found that bind certain cytokines with high affinity. Materials and methods for making compositions and devices using these peptides are disclosed.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 10, 2017
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Mikael Martino, Laura De Laporte, Jeffrey J. Rice, Federico Tortelli
  • Patent number: 9505802
    Abstract: The present invention relates to a method for the isolation of proteins that comprise disulfide-bonds in their native conformation. Essentially, a method of the present makes the use of reducing agents such as ?-mercaptoethanol or dithiothreitol in protein isolation methods obsolete. A method of the present invention is particularly suitable for the isolation of precursor proteins such as proinsulin from recombinant cells.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: November 29, 2016
    Assignee: MSD OSS B.V.
    Inventors: Peter Van Der Meijden, Gijsbert Willem Karel Van Dedem, Michel Hendrikus Maria Eppink, Roeland Wilhelmus Wassenaar
  • Patent number: 9474800
    Abstract: The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: October 25, 2016
    Assignee: FIT Biotech OY
    Inventors: Kaja Kiiver, Rein Sikut, Urve Toots, Tarmo Mölder, Andres Männik, Mart Ustav, Katrin Kaldma
  • Patent number: 9453251
    Abstract: The invention is a process for improved production of a recombinant mammalian protein by expression in a Pseudomonad, particularly in a Pseudomonas fluorescens organism. The process improves production of mammalian proteins, particularly human or human-derived proteins, over known expression systems such as E. coli in comparable circumstances Processes for improved production of isolated mammalian, particularly human, proteins are provided.
    Type: Grant
    Filed: January 18, 2005
    Date of Patent: September 27, 2016
    Assignee: PFENEX INC.
    Inventors: Diane M. Retallack, Charles H. Squires, David C. Watkins, Stacey L. Lee, Frank H. Gaertner, Robert Shutter
  • Patent number: 9441026
    Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: September 13, 2016
    Assignee: The Board of Trustees of the Leland Standford Junior University
    Inventors: Jennifer R. Cochran, Adam Silverman, Douglas Jones, Niv Papo
  • Patent number: 9409983
    Abstract: The present invention concerns methods and compositions involving inhibitors of Pre-B Cell Colony Enhancing Factor (PBEF) for inflammatory conditions and diseases, including acute lung injury (ALI), ventilator-induced lung injury (VILI), and acute respiratory distress syndrome (ARDS). The present invention also concerns biomarkers for inflammation as well as methods for screening for PBEF inhibitors.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: August 9, 2016
    Assignee: The Board of Trustess of the University of Illinois
    Inventor: Joe G. N. Garcia
  • Patent number: 9403892
    Abstract: This invention relates to the biotechnology area, and provides a kind of TRAIL chimeric protein, DNA sequence encoding this chimeric protein, vectors comprising this DNA, host cells or transgenic animals that contain one of the vectors, and preparation methods for the said chimeric protein and its applications. The said TRAIL fusion protein from the N to C terminal comprises human leucine zipper sequence, human TRAIL protein, human TRAIL extracellular domain or a fragment thereof. The chimeric protein has significantly enhanced stability, prolonged half-life in animals, increased efficacy and thus has broad application future.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: August 2, 2016
    Assignee: MAGELLAN PHARMA CO. LTD.
    Inventors: Bing Zhou, Yu Zhou, Jing Jiang
  • Patent number: 9376381
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of peptides and peptide-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: June 28, 2016
    Assignee: Techfields Pharma Co., Ltd.
    Inventor: Chongxi Yu
  • Patent number: 9375473
    Abstract: The invention relates to methods of preventing or inhibiting the onset and/or treating autoimmune demyelinating neuropathy and other autoimmune or inflammatory diseases involving macrophage infiltration.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: June 28, 2016
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Norman Latov, Grace Lee
  • Patent number: 9359645
    Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: June 7, 2016
    Assignees: HUBIT GENOMIX INC.
    Inventors: Toshio Doi, Hideharu Abe
  • Patent number: 9296804
    Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: March 29, 2016
    Assignee: Bolder Biotechnology, Inc.
    Inventors: George N. Cox, Mary S. Rosendahl
  • Patent number: 9273110
    Abstract: Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: March 1, 2016
    Assignee: Amgen Inc.
    Inventors: Christopher Kenyon Crowell, Gustavo Enrique Grampp
  • Patent number: 9248109
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of peptides and peptide-related compounds, which are capable of crossing biological barriers with higher penetration efficiency comparing to their parent drugs. The HPPs are capable of being converted to parent drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs/HPCs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs/HPCs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: February 2, 2016
    Inventors: Chongxi Yu, Lina Xu, Yuhua Chen, Binbing Yan, Shiqian Tu
  • Patent number: 9169309
    Abstract: The present technology relates to engineered human Fibroblast Growth Factor-2 (FGF2) proteins and methods of using the same. In particular, the methods and compositions relate to FGF2 mutants with increased thermostability compared to the wild-type protein and method for using the proteins in the culturing of embryonic stem cells.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: October 27, 2015
    Assignee: HUMANZYME INC.
    Inventor: Soon Seog Jeong
  • Patent number: 9168214
    Abstract: It has been discovered that vascular endothelial growth factor (“VEGF”) promotes migration of activated (but not differentiating) keratinocytes to skin. This growth factor specifically increases migration of keratinocytes of the “wounded skin” phenotype but does not have significant effects upon differentiated keratinocytes. It also increases collagen deposition and reduces wrinkles, enhances skin quality, and increases skin thickness to normal levels in individuals where skin has thinned due to age or disorder such as diabetes. It is particularly well suited for use as cosmeceuticals when applied in purified form and in known amounts. The data presented in the examples demonstrate efficacy and specificity of VEGF in enhancing migration of normal human keratinocytes as well as formation of new granulation tissue including collagen formation. VEGF induces keratinocyte and fibroblast migration, formation of new tissue, and not only induces deposition of collagen but improves alignment of the collagen fibers.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: October 27, 2015
    Assignee: New York University
    Inventors: Harold Brem, Marjana Tomic-Canic
  • Patent number: 9133244
    Abstract: Peptide antagonists of ?c-family cytokines, Interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21 are described. The ?c-cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic, cosmetic agents and research tools. Traditional approaches to inhibiting ?c-cytokine activity involve raising neutralizing antibodies against each individual ?c-cytokine family member/receptor subunit. However, success has been limited and often multiple ?c-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. To overcome these shortcomings, use of peptide antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity is provided.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: September 15, 2015
    Assignee: BIONIZ, LLC
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 9133440
    Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: September 15, 2015
    Inventor: Claresa Levetan
  • Patent number: 9078860
    Abstract: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: July 14, 2015
    Assignee: Trophogen, Inc.
    Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
  • Patent number: 9074194
    Abstract: This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed thereby, and pharmaceutical compositions that contain all these elements. These compositions may be used in the treatment of diseases from the following group: ageing or acceleration of ageing, neurodegenerative diseases and dyskeratosis congenita.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: July 7, 2015
    Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, UNIVERSIDAD AUTONOMA DE MADRID—FUNDACION GENERAL, UNIVERSIDAD POLITECNICA DE VALENCIA
    Inventors: Rosario Perona Abellon, Rosario Machado Pinilla, Leandro Sastre Garzon, Isabel Sanchez Perez, Jose Ramon Murguia Ibanez
  • Patent number: 9066908
    Abstract: The invention provides use of a TSG-6 polypeptide, or a polynucleotide encoding an TSG-6 polypeptide, in the manufacture of a medicament for the treatment or prevention of a bone disease or condition associated with bone resorption by osteoclasts.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: June 30, 2015
    Assignee: University of Manchester
    Inventors: Afsie Sabokbar, Anthony Day, Caroline Milner
  • Publication number: 20150147292
    Abstract: The present invention is based in part on the discovery of brown and white fat cell specific surface markers. It has been found that the small amino acid transporter Slca10/Asc1 is a specific surface marker for white adipocytes and that the ligand-gated ion channel P2X5 and the small amino acid transporter Slc36a2 are specific surface markers for brown adipocytes. Having identified these specific white and brown cell surface markers, the present invention provides compositions and methods suitable for the targeting of any number of agents to a white or brown adipose tissue and the identification and isolation of white or brown adipocytes for any number of uses including therapeutic, screening and diagnostic purposes.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 28, 2015
    Applicant: Joslin Diabetes Center, Inc.
    Inventors: C. Ronald Kahn, Siegfried Ussar
  • Publication number: 20150148293
    Abstract: Mutant fibroblast growth factor (FGF) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the Fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human FGF-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human FGF-1 with a tryptophan (based on the 140 amino acid numbering scheme of human FGF-1) are provided. Other amino acid mutations or substitutions may be combined. Polynucleotide sequences encoding the mutant FGF proteins and host cells containing such polynucleotide sequences are provided. Methods of administering a mutant FGF protein to an individual to treat an ischemic condition or disease or a wound or tissue injury are also provided.
    Type: Application
    Filed: January 9, 2015
    Publication date: May 28, 2015
    Inventors: MICHAEL BLABER, JIHUN LEE
  • Publication number: 20150147404
    Abstract: LEDGF peptides with anti-protein aggregation activity and methods of use are provided. The LEDGF peptides disclosed herein demonstrate an ability to treat degenerative diseases and diseases with various cellular stresses including oxidative stress and protein-aggregation stress. In addition, extended release formulations, including formulations suitable for ophthalmic administration are provided.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 28, 2015
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Uday B. Kompella, Rinku Baid, Arun K. Upadhyay, Sarath Yandrapu
  • Publication number: 20150140005
    Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Keith R. Walley, John H. Boyd, James A. Russell
  • Publication number: 20150141327
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.
    Type: Application
    Filed: June 5, 2013
    Publication date: May 21, 2015
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Publication number: 20150141627
    Abstract: The present invention relates to a novel method for an antigen and/or bioactive molecule delivery and a composition that functions in the antigen and/or bioactive molecule delivery comprising the ASC speck carrier and the antigen and/or bioactive molecule, carried by the ASC speck carrier.
    Type: Application
    Filed: April 18, 2013
    Publication date: May 21, 2015
    Inventors: Ali Can Sahillioglu, Nesrin Ozoren
  • Patent number: 9034826
    Abstract: The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as in ischemic neuritis.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: May 19, 2015
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jose Ignacio Fernandez Montequin, Luis Saturnino Herrera Martinez, Jorge Amador Berlanga Acosta, Diana Garcia Del Barco Herrera, Danay Cibrian Vera, Gerardo Enrique Guillen Nieto, Raimundo Ubieta Gomez, Sonia Gonzalez Blanco, Vivian Maria Saez Martinez
  • Publication number: 20150133379
    Abstract: The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein. The fusion protein significantly enhances the skin penetration and skin retention of the physiologically active protein while maintaining or enhancing the ability of the physiologically active protein to synthesize a material showing physiologically active effects. Thus, it can be widely used as an active ingredient in functional cosmetic compositions and pharmaceutical compositions for external skin use.
    Type: Application
    Filed: April 30, 2014
    Publication date: May 14, 2015
    Inventors: Seol Hoon Lee, Sang Hwa Lee, Nae Gyu Kang, Eu Gene Hur
  • Patent number: 9029328
    Abstract: The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: May 12, 2015
    Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of Technology
    Inventors: Steven M. Jay, Linda G. Griffith, Richard T. Lee
  • Patent number: 9029323
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: May 12, 2015
    Assignee: Evotec International GmbH
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Patent number: 9029330
    Abstract: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: May 12, 2015
    Assignee: Merck Patent GmbH
    Inventors: Gordon D. Webster, Suzanne P. McKenzie, Kin-Ming Lo, Pascal André Stein
  • Publication number: 20150125423
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 7, 2015
    Inventors: Jennifer Mitcham, Matthew Moyle
  • Publication number: 20150126715
    Abstract: The present invention relates to a long-acting human growth hormone NexP-hGH protein and its production method. More specifically, it relates to a specific isoform of long-acting human growth hormone NexP-hGH protein in which human growth hormone is fused with a highly glycosylated alpha-1 antitrypsin mutant whereby long-acting properties in vivo are increased.
    Type: Application
    Filed: June 5, 2013
    Publication date: May 7, 2015
    Inventors: Gil Bu Kang, Chung Min Lee, Jee Won Ahn, Dong Eok Lee, Chang Bong Jun, Won Jeong Lee, Sung Yoo Cho, Chi Hye Park, Ki Wan Kim, Yoon Jung Lee, Ji Hyun Moon, Hoo Keun Oh, Young Joon Park, Sang Hyun Lee, Hyoung Taek Lim, Soon Jae Park, Hye Shin Chung, Sang Mee Lee
  • Publication number: 20150126446
    Abstract: The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding affinity. These variants have been found to act as receptor antagonists for VEGF receptors and antagonize angiogenesis. These variants are useful to treat diseases characterized by pathological angiogenesis.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 7, 2015
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health & Human Services
    Inventors: Donald P. Bottaro, Fabiola Cecchi
  • Patent number: 9023791
    Abstract: The present invention provides novel polypeptide and protein variants of fibroblast growth factor 21 (FGF21) and pharmaceutical compositions comprising FGF21 polypeptide and protein variants.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: May 5, 2015
    Assignees: Novartis AG, IRM LLC
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Bernhard H. Geierstanger, Norio Hamamatsu, Stuart Licht, Andreas Loew, Stephen Craig Weldon
  • Publication number: 20150118185
    Abstract: Compositions containing conjugates of heparosan polymer with at least one drug are disclosed, along with methods of production and use thereof.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 30, 2015
    Inventor: Paul L. DeAngelis
  • Patent number: 9018165
    Abstract: A method for synchronizing ovulation in sows and gilts without heat detection by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred without heat detection at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: April 28, 2015
    Inventor: James W Lauderdale
  • Patent number: 9018357
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 28, 2015
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Publication number: 20150110885
    Abstract: The present invention describes novel and improved parenteral depot pharmaceutical compositions containing cosyntropin (tetracosactide), for the treatment of infantile spasm.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Giancarlo SANTUS, Luca DONADONI, Leticia Khater COVESI